Abstract-Nuclear factor-B (NF-B) regulates many genes involved in vascular physiopathology. We have previously observed in vivo NF-B activation in injured vessels that diminished by angiotensin-converting enzyme inhibition. In the present work, we investigated the effect of angiotensin II (Ang II) on NF-B activity in rat vascular smooth muscle cells, evaluating the molecular mechanisms and the specific receptor subtype involved. Ang II increased NF-B DNA binding (5-fold, 10 Ϫ9 mol/L at 1 hour; electrophoretic mobility shift assay), nuclear translocation of p50/p65 subunits, and cytosolic inhibitor B␣ (IB␣) degradation. Ang II elicited NF-B-mediated transcription (transfection of a reporter gene) and expression of NF-B-related genes (monocyte chemoattractant protein-1 and angiotensinogen). AT 1 (DUP753) and AT 2 (PD123319 and CGP42112) receptor antagonists inhibited Ang II-induced NF-B DNA binding in a dose-dependent manner (Ϸ85% for each one; 10 Ϫ5 mol/L at 1 hour). The AT 2 agonist p-aminophenylalanine 6 -Ang II augmented NF-B binding (4.6-fold, 10 Ϫ9 mol/L at 1 hour), p65 nuclear levels, and transcription of an NF-B reporter gene. AT 1 antagonist markedly inhibited NF-B-mediated transcription and gene expression. Some differences between AT 1 /AT 2 intracellular signals were found. Antioxidants and ceramide inhibitors, but not protein kinase C inhibitors, diminished NF-B activation elicited by both Ang II and the AT 2 agonist, while tyrosine kinase inhibitors only decreased Ang II-induced NF-B activity. Our results demonstrate that Ang II activates NF-B via AT 1 and AT 2 , although NF-B-mediated transcription occurred mainly through AT 1 . Both receptors share some signaling pathways (oxygen radicals and ceramide); however, tyrosine kinases only participate in AT 1 /NF-B responses. These data provide novel insights into Ang II actions, suggesting a potential implication of the AT 2 in the pathobiology of vascular cells.
A ngiotensin II (Ang II) is the main effector peptide of the renin-angiotensin system that plays an important role in several cardiovascular diseases associated with vascular smooth muscle cell (VSMC) growth and inflammation, including hypertension, atherosclerosis, restenosis after balloon injury, and myocardial infarction. 1 Ang II exerts its biological effects through the stimulation of specific receptors located on the cell surface. The use of selective antagonists has revealed the heterogeneity of Ang II receptors (AT-Rs), 2 and different cDNAs corresponding to each receptor have been isolated. 2, 3 AT 1 mediates many important cardiovascular responses, such as vasoconstriction, vascular and cardiac remodeling, and cell survival/death [1] [2] [3] and evokes several intracellular signals such as calcium mobilization and activation of protein kinases, including protein kinase C (PKC) and mitogen-activated protein (MAP) cascade. 4 AT 2 is involved in some Ang II actions, including apoptosis and inflammatory cell recruitment, and elicits different second messengers, such as MAP phosphatase activation and kinase inhibition. 3, 5 Recent studies have shown that Ang II activates some nuclear transcription factors. In VSMCs, Ang II activates the signal transducer and activator transcription factor (STAT) and activator protein-1 (AP-1) through AT 1 . 6, 7 We have recently demonstrated that Ang II activates nuclear factor-B (NF-B) in VSMCs and mesangial cells. 8, 9 However, AT-R subtype and molecular mechanisms of this process have not been elucidated. NF-B could play an important role in cardiovascular pathophysiology through the regulation of several genes, including cytokines, adhesion proteins, NO synthase, and angiotensinogen, as well as other products involved in atherosclerosis, inflammation, proliferation, and immune response. 10, 11 Elevated tissular NF-B activity has been described in an experimental model of atherosclerosis, correlated with increased macrophage infiltration and monocyte chemoattractant protein-1 (MCP-1) expression, which diminished by angiotensin-converting enzyme (ACE) inhibition, 8 and also in a model of endothelial damage coincidentally with leukocyte adhesion molecule expression. 12 These data suggest that NF-B could be involved in the pathogenesis of several cardiovascular diseases, such as atherosclerosis and hypertension.
In the present study, we demonstrate that in cultured rat VSMCs, Ang II activates NF-B by a mechanism mediated by both AT 1 and AT 2 . These results show new concepts of AT-R-mediated cell signaling in the cardiovascular system and could be important for a better understanding of the implication of Ang II in the pathogenesis of vascular damage.
Materials and Methods
Thoracic aortic rat VSMCs were serum starved for 48 hours and used for experiments. AT 2 and angiotensinogen mRNA expression were analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR), and MCP-1 expression was analyzed by Northern blot.
Western Blot and Immunohistochemistry for AT-R
Total proteins were resolved in 12% SDS-PAGE gels, transferred, blocked, and incubated with specific AT 2 and AT 1 antibodies for 18 hours at 4°C. Detection was performed with peroxidase-conjugated secondary antibody and developed using an enhanced chemiluminescence kit (Amersham). For immunoperoxidase staining, cells were fixed in methanol/acetone at -20°C and incubated with primary antibodies and then with peroxidase-conjugated secondary antibody.
NF-B DNA Binding Activity
Nuclear and cytosolic extracts were prepared by homogenization and centrifugation. 8, 9 NF-B activity was determined in nuclear extracts by binding with labeled NF-B consensus and analyzed by electrophoretic mobility shift assay (EMSA). To quantify nuclear p50 and p65 levels and cytosolic IB␣ and IB␤, Western blot analyses were done. For immunofluorescence staining, cells were fixed in 3% paraformaldehyde for 10 minutes on ice followed by 0.1% Triton X-100 for 1 minute and then incubated with antibodies against p50/p65 subunits and with FITC-labeled IgG as secondary antibody.
Transient Transfections and Luciferase Assay
Double transient transfections of growth-arrested VSMCs with NF-B/luc and thymidine kinase (TK)-Renilla were performed by particle-mediated gene transfer, with the Biolistic PDS-1000/He System (Bio-Rad Laboratories) and gold microcarriers coated with DNA, into quiescent VSMCs. 13 After transfection, cells were serum starved for 24 hours before stimulation. Lysates were assayed for luciferase and Renilla activities (Promega).
Statistical Analysis
Results are expressed as n-fold increase over control in densitometric arbitrary units and as meanϮSEM of the experiments performed. Significance was established using the GraphPAD Instat program with the Student t test; differences were considered significant if the P value was Ͻ0.05.
An expanded Materials and Methods section is available online at http://www.circresaha.org.
Results
Ang II Activates NF-B Through AT 1 and AT 2 in Cultured Rat VSMCs Ang II increased NF-B DNA binding activity at as early as 30 minutes, peaked at 1 hour, and declined by 2 hours. The maximal response was observed with 10 Ϫ9 mol/L Ang II (5-fold over control, nϭ10, PϽ0.05), with an intensity similar to that of 100 U/mL tumor necrosis factor-␣ (TNF-␣) ( Figure 1A ). VSMCs were preincubated with specific AT-R antagonists, DUP753 for AT 1 and PD123319 for AT 2 . Both antagonists partially blocked the Ang II-induced NF-B DNA binding activity at all time points. The maximal inhibitory effect was found after 30 minutes ( Figure 1B) . The inhibitory effect of each antagonist was dose dependent, being maximal with 10 Ϫ5 mol/L (88% and 84% inhibition versus Ang II alone, for DUP753 and PD123319, respectively, after 1 hour; nϭ6, PϽ0.05) ( Figure 1C ). When both antagonists were added simultaneously, a marked inhibition of the Ang II effect was observed (96% inhibition, 10 Ϫ5 mol/L, nϭ3). Neither DUP753 nor PD123319 alone significantly affected NF-B activation in unstimulated cells (0.94-and 1-fold over control, respectively; nϭ6, PϭNS) ( Figure  1C ). In VSMCs, CGP42112 has been used to demonstrate AT 2 binding sites. 14 CGP42112 alone activated NF-B, maximal at 10 Ϫ5 mol/L (4.5-fold over control; nϭ4, Pϭ0.05) showing an agonist effect, as previously reported. 2 CGP42112 blocked Ang II action (10 Ϫ5 mol/L, 82% inhibition versus Ang II alone, at 1 hour; nϭ4, PϽ0.05). To further demonstrate that the receptor subtype was associated with NF-B activation, we used an AT 2 agonist, p-aminophenylalanine 6 -Ang II (pNH 2 FAII). 15 Treatment for 1 hour with pNH 2 FAII increased NF-B DNA binding activity in a dose-dependent manner ( Figure 1D ), with a maximal response at 10 Ϫ9 mol/L (4.6-fold, nϭ4, PϽ0.05). The specificity was demonstrated by the fact that only PD123319 blocked the pNH 2 FAII-induced NF-B activation ( Figure 1D ). On the whole, these results suggest that Ang II-induced NF-B DNA binding activity was mediated by both AT 1 and AT 2 .
We have also observed that, in our experimental conditions, VSMCs express AT 2 at gene and protein levels (see online Materials and Methods, available at http://www.circresaha.org). These data are in agreement with previous studies showing detectable AT 2 binding sites in cultured VSMCs. 14 
Ang II Translocates p50/p65 NF-B Complexes Into the Nuclei and Degrades Cytosolic Inhibitor B (IB)
We have studied the composition of NF-B complexes induced by Ang II in rat VSMCs (see online Materials and Methods, available at http://www.circresaha.org). By supershift assays, we have observed that the NF-B complex activated is a p50/p65 heterodimer. After 1 hour of Ang II stimulation, a translocation of p50 and p65 subunits from cytosol to nuclei was observed (immunofluorescence and Western blot). pNH 2 FAII upregulated nuclear p50 and p65 levels, with a maximal response at 10 Ϫ9 mol/L and with an intensity and kinetics similar to those of Ang II. These data suggest that AT 2 is involved in the transcriptional regulation of NF-B-controlled genes. NF-B activation involves dissociation of IB by phosphorylation and subsequent degradation. 10 On Ang II stimulation, cytosolic IB␣ was rapidly degraded, whereas IB␤ remained unchanged. This effect was closely correlated with the time course of Ang II on NF-B activation and with the translocation of p50/p65 to the nuclei. After 2 hours, Ang II treatment increased cytosolic IB␣ levels, probably because of new protein synthesis.
When cells were pretreated with either AT 1 or AT 2 antagonists, an inhibition of Ang II-induced IB␣ degradation was observed (Figure 2 ), suggesting that both receptors participate in this process.
Molecular Mechanisms of Ang II-Induced NF-B Activation
We next investigated which intracellular signaling responses elicited by Ang II could be involved in NF-B activation in VSMCs, trying to elucidate differences between AT 1 and AT 2 Figure 3B ). In contrast, they had no effect on the AT 2 agonist ( Figure 3B ), suggesting that activation of PTK could be involved in Ang II-induced NF-B response via AT 1 . NF-B activation is also mediated by active oxygen radicals. 16 Structurally diverse antioxidants markedly diminished the NF-B activation elicited by Ang II and the AT 2 agonist pNH 2 FAII ( Figure 3C ). Another possible signaling pathway of NF-B activation could involve ceramide production. 17 The inhibitor of ceramide synthase fumonisin B 1 inhibited the NF-B activation induced by Ang II and pNH 2 FAII ( Figure  3D ), suggesting that ceramide could be a mediator of Ang II/AT 2 -induced NF-B activation.
Effect of Ang II on NF-B-Mediated Gene Transcription
To investigate the effects of the Ang II receptor antagonists on NF-B-mediated gene expression, two different strategies were followed; these were transient transfection with a reporter plasmid containing NF-B promoter binding sites and gene expression analysis of NF-B-related genes.
Growth-arrested VSMCs were cotransfected with NF-B/ luc and TK-Renilla (internal control) by Biolistic gene transfer. Then, cells were serum starved for 24 hours before stimulation with 10 Ϫ7 mol/L Ang II or phorbol 12-myristate 13-acetate (PMA) for an additional 24 hours, and luciferase activity was measured. Ang II activated the expression of the reported NF-B/luc plasmid (6-fold versus control; nϭ5, PϽ0.05), with a similar response to PMA. No increase was seen with the control plasmid (not shown). pNH 2 FAII also increased luciferase activity (3.7-fold, PϽ0.05; Figure 4 ). When cells were pretreated with either AT 1 or AT 2 antagonists, a partial decrease of Ang II-induced NF-B-mediated transcription was observed that was completely blocked when both antagonists were added together (Figure 4 , 95% inhibition versus Ang II alone; nϭ4, PϽ0.05). Interestingly, the inhibitory effect of DUP753 was higher than that of PD123319, suggesting that although Ang II increases NF-B-mediated transcription through AT 1 or AT 2 , the AT 1 / NF-B pathway seems to be more active.
We further evaluated the role of AT-R in some NF-Bcontrolled genes. Ang II stimulation increased MCP-1 mRNA levels at as early as 3 hours, being maximal at 6 hours (10 Ϫ7 mol/L; 5-fold versus control, nϭ5, PϽ0.05, Northern blot) and diminished after 24 hours, as previously shown. 8, 9 DUP753 significantly diminished Ang II-induced MCP-1 gene expression ( Figure 5 ), whereas PD123319 only produced a slight decrease. pNH 2 FAII also increased MCP-1 mRNA but to a lesser extent than Ang II ( Figure 5 ). In addition, inhibitors of NF-B activation, MG132 ( Figure 5B) , gliotoxin, and pyrrolidine dithiocarbamate (not shown) diminished MCP-1 mRNA induction caused by Ang II. By RT-PCR, Ang II upregulated angiotensinogen mRNA at 6 hours, which was only diminished by DUP753 ( Figure 5B ). These data suggest that MCP-1 and angiotensinogen gene expression were mainly mediated by AT 1 .
Discussion
Ang II acts through two specific receptor subtypes, AT 1 and AT 2 . AT 1 predominates in vascular tissues and is responsible for most of the physiopathological actions of Ang II. 2,3 AT 2 is mainly present in fetal tissues and is reexpressed in pathological conditions, such as myocardial infarction and cardiac hypertrophy, 3 as well as in cultured VSMCs, 14 as shown in this article. Pharmacological and molecular tools are contributing to the elucidation of the AT 1 /AT 2 functions. Specific receptor antagonists have demonstrated that AT 1 is involved in cell proliferation, production of cytokines, and matrix proteins, 2, 3, 18 and in the pathogenesis of Ang II-induced hypertension and cardiac hypertrophy. 19, 20 AT 2 participates in cell growth inhibition, neointimal formation after vascular injury, trophic effects of VSMCs, and blood pressure control. 3 Some Ang II responses could be mediated by both receptors, including NO release, collagen synthesis and ␣-2-adrenoreceptor activity. [21] [22] [23] In VSMCs we have demonstrated that both AT 1 and AT 2 activate nuclear NF-B DNA binding activity that is functional in its ability to transactivate B-containing promoters. The AT 1 antagonist markedly inhibited NF-B-mediated gene transcription. Ang II via AT 1 increases interleukin (IL)-6 and angiotensinogen mRNA through an NF-B-mediated transcriptional mechanism. 11, 18 In the same way, Ang II-induced MCP-1 mRNA was diminished by AT 1 antagonist and by different NF-B inhibitors. However, AP-1 and NF-B cooperate in the MCP-1/ IL-1␤ response, 24 showing a potential role for other transcription factors. Ang II-induced hypertension in rats is characterized by marked monocyte infiltration and vascular cell adhesion molecule and MCP-1 expression in the aorta. 25, 26 ACE inhibitors reduce the presence of monocyte/macrophages in the vessel wall of hypertensive rats. 27 In an experimental model of atherosclerosis, ACE inhibition diminished NF-B activity and chemokine expression in the lesion. 8 All of these data suggest that Ang II could contribute to inflammatory events in atherosclerosis and hypertension through vascular inflammatory genes, by the AT 1 /NF-B pathway. In contrast, we have observed that an AT 2 agonist increased NF-B DNA binding and mediated gene transcription. AT 2 upregulates the chemokine RANTES and renal inflammatory cell recruitment, 5 showing a possible gene target for the AT 2 /NF-B pathway. These data suggest that Ang II, acting mainly via AT 1 , and in particular conditions through AT 2 , could regulate several NF-B-related genes involved in the pathogenesis of cardiovascular diseases.
NF-B has been implicated in the transcription of genes mediating cell growth control, but its role in growth regulation remains to be established. The development of atherosclerotic fibrous plaques is due to activation of VSMCs, which proliferate and increase matrix deposition. Activation of NF-B has been observed in human atherosclerotic lesions and in cultured VSMCs in a proliferative state. 8, 12 Apoptosis of VSMCs and macrophages has been found in atherosclerotic lesions. 28 In most cell types, NF-B mediates cell survival signals, protecting cells from apoptosis, but under certain conditions it may also induce apoptosis. 29 In vitro experiments suggest that Ang II may cause growth via AT 1 and apoptosis via AT 2 . In vivo, stimulation of AT 1 or AT 2 causes apoptosis in the media of blood vessels. 30 Among the intracellular mechanisms elicited by AT 2 , ceramide production seems to be involved in apoptosis 31 and NF-B activa- tion. A similar behavior was observed with TNF-␣, which increases ceramide production; activates NF-B; and, depending on cell culture conditions, causes cell proliferation or apoptosis. Although many studies have been done, future work is necessary to completely understand the in vivo relation between NF-B, cell growth/apoptosis, and the role of AT-R in these processes.
AT 1 and AT 2 are coupled to G proteins and belong to the 7-transmembrane-domain receptor family. 2 Although the intracellular signalings elicited after activation of the AT 1 and AT 2 are different, our data suggest that both receptors share a common molecular pathway: the activation of NF-B. Many agents activate NF-B, but the mechanisms are not well understood. 10 Recently, 2 different pathways leading to NF-B activation have been suggested, because sanguinarine blocked NF-B activation caused by okadaic acid, PMA, TNF-␣, and IL-1␤, but not by ceramides and H 2 O 2 . 32 Reactive oxygen metabolites (reactive oxygen species; ROS) serve as common intracellular agents for NF-B by a wide range of stimuli. We have demonstrated that a variety of structurally diverse antioxidants blocked the activation of NF-B elicited by Ang II and AT 2 agonist, suggesting that ROS act as intermediates of both AT 1 /AT 2 , as occurs with TNF-␣ and IL-1␤. 32 Antioxidants also mediate other Ang II effects, mainly through AT 1 , such as AP-1 activation, cell proliferation, and protein synthesis. 2, 3, 7 Some differences between AT 1 and AT 2 signaling systems were found. PTK inhibitors diminished Ang II-induced NF-B activation but had no effect on AT 2 agonist, showing that PTK mediates only the AT 1 /NF-B pathway. In contrast, PKC is not involved in Ang II-induced NF-B activation. The role of PKC on NF-B seems to be cell/stimulus specific, given that it mediates H 2 O 2 action 33 but has no effect on TNF-␣ and IL-1␤. 34 Some signaling mechanisms of AT 1 are similar to those used by cytokines, such as activation of the PTK, PKC, MAP kinase (MAPK), Janus kinase (JAK)/STAT, and AP-1 pathways. 4 The JAK/STAT system activates ROS-sensitive PTK, 16 which could participate in NF-B activation. MAPK is required for the activation of several transcription factors, including NF-B, 35 but how p38 MAPK may affect NF-B function is unclear. The inhibitor of p38 MAPK SB203580 abolished TNF-␣-induced cytokine synthesis and blocked NF-B-mediated luciferase transactivation in response to TNF-␣ without affecting NF-B translocation. 36 Ang IIinduced MCP-1 gene expression via AT 1 is dependent on redox-sensitive signals and on activation of PTK and MAP. 37 All of these data suggest a potential mechanism of AT 1 /NF-B/gene regulation, via ROS and PTK, that is common to proinflammatory cytokines as TNF-␣ and IL-1␤. The AT 2 is linked to inhibition of MAP kinase, activation of proteinphosphotyrosine phosphatase, and changes in phospholipase A 2 activity. 2, 3 Phosphorylation of IB is a prerequisite for its degradation and subsequent liberation of active NF-B. For this reason, after stimulation of AT 2 , we could expect activation of some phosphatases that may regulate IB degradation. However, AT 2 activates NF-B (DNA binding and gene transcription), suggesting that Ang II-induced phosphatases are not involved in this process. In addition, the phosphatase inhibitor okadaic acid activates NF-B by a process independent of phosphatase inhibition but dependent on ROS. 26 Ceramide production is a second messenger for AT 2 , via G protein and phosphatase activation, and an essential step in programmed cell death. 31 Moreover, ceramide generated by sphingomyelin breakdown by sphingomyelinase mediated TNF-␣ and IL-1␤ NF-B activation. 17 Given that a ceramide inhibitor diminished Ang II and AT 2 -induced NF-B activation, ceramide could be a potential mediator of the AT 2 / NF-B pathway.
In summary, our results show that in cultured rat VSMCs, AT 1 and AT 2 mediate Ang II-induced NF-B activation. Both receptors share some intracellular signals in the Ang II /NF-B pathway, such as ROS and ceramide production, but PTK only mediates the AT 1 /NF-B pathway. These signaling mechanisms are similar to those used by proinflammatory cytokines, such as IL-1␤ and TNF-␣, providing a point for "cross talk" between Ang-and cytokine-activated second messenger pathways, and supporting the emerging idea of Ang II as a true cytokine. Ang II-mediated gene transcription occurred mainly through AT 1 , because the AT 1 antagonist markedly inhibited NF-B-mediated gene transcription and Ang II-induced overexpression of related genes, such as angiotensinogen, chemokines (MCP-1), cytokines, 18 and adhesion molecules, 26 involved in the development of atherosclerosis. Finally, our data also show a novel action of AT 2 , the activation of NF-B, which suggests a potential involvement in the pathogenesis of cardiovascular diseases.
